AR045564A1 - Forma de dosificacion en forma de multiples particulas, formulada mediante fusion . preparado de combinacion farmaceutica - Google Patents

Forma de dosificacion en forma de multiples particulas, formulada mediante fusion . preparado de combinacion farmaceutica

Info

Publication number
AR045564A1
AR045564A1 ARP040103150A ARP040103150A AR045564A1 AR 045564 A1 AR045564 A1 AR 045564A1 AR P040103150 A ARP040103150 A AR P040103150A AR P040103150 A ARP040103150 A AR P040103150A AR 045564 A1 AR045564 A1 AR 045564A1
Authority
AR
Argentina
Prior art keywords
dosage form
formulated
pharmaceutical combination
preparation
fusion
Prior art date
Application number
ARP040103150A
Other languages
English (en)
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34202401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR045564(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR045564A1 publication Critical patent/AR045564A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forma de dosificación oral, en forma de múltiples partículas, formulada mediante fusión, que contiene ácido clavulánico y/o al menos una de sus sales aceptables fisiológicamente así como también uno o más ésteres grasos de sacarosa y opcionalmente otros adyuvantes adicionales aceptables fisiológicamente, así como a un método para su preparación y así como a su utilización. Reivindicación 22: Preparado de combinación farmacéutico caracterizado en que contiene una forma de dosificación según una de las reivindicaciones 1 a 16 y otra forma de dosificación oral, formulada separadamente de la anterior, que contiene como principio activo farmacéutico al menos un antibiótico beta-lactámico, preferiblemente amoxicilina. Reivindicación 25: Preparado de combinación farmacéutico según una de las reivindicaciones 22 a 24 caracterizado en que es para el tratamiento de infecciones bacterianas, preferiblemente de infecciones bacterianas en niños.
ARP040103150A 2003-09-04 2004-09-02 Forma de dosificacion en forma de multiples particulas, formulada mediante fusion . preparado de combinacion farmaceutica AR045564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10341264A DE10341264A1 (de) 2003-09-04 2003-09-04 Schmelzformulierte, multipartikuläre orale Darreichungsform

Publications (1)

Publication Number Publication Date
AR045564A1 true AR045564A1 (es) 2005-11-02

Family

ID=34202401

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103150A AR045564A1 (es) 2003-09-04 2004-09-02 Forma de dosificacion en forma de multiples particulas, formulada mediante fusion . preparado de combinacion farmaceutica

Country Status (15)

Country Link
US (1) US7666860B2 (es)
EP (1) EP1663160B1 (es)
CN (1) CN100548276C (es)
AR (1) AR045564A1 (es)
AT (1) ATE355830T1 (es)
DE (2) DE10341264A1 (es)
ES (1) ES2284049T3 (es)
HK (1) HK1092715A1 (es)
IL (1) IL174009A (es)
MX (1) MXPA06002530A (es)
PE (1) PE20051041A1 (es)
PL (1) PL1663160T3 (es)
PT (1) PT1663160E (es)
SI (1) SI1663160T1 (es)
WO (1) WO2005023216A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006007830A1 (de) * 2006-02-17 2007-08-30 Grünenthal GmbH Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure
EP1900358A1 (en) * 2006-09-16 2008-03-19 Cimex Pharma AG Pharmaceutical formulations comprising clopidogrel
DE102006059510A1 (de) 2006-12-14 2008-06-19 Grünenthal GmbH Beschichtete Pellets
CA2872689C (en) * 2012-05-07 2021-03-30 Echo Pharmaceuticals B.V. Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
HUP1500164A2 (en) * 2015-04-14 2016-10-28 Ferenc Ecseri Filled straw with edible homogeneous structured granules and process for producing thereof
KR20190039137A (ko) 2016-07-14 2019-04-10 아카오젠, 인코포레이티드 박테리아 감염 치료에서 사용하기 위한 세프티부텐과 클라불란산의 조합

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5675437A (en) * 1979-11-21 1981-06-22 Asahi Denka Kogyo Kk Suppository base
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
JPH05219885A (ja) * 1992-02-14 1993-08-31 Mitsubishi Kasei Corp クリームリカー組成物
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
US6217545B1 (en) 1999-02-08 2001-04-17 Porex Technologies Corp. Filter with varying density which is responsive to fluid flow
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
CZ20023009A3 (cs) * 2000-03-08 2003-06-18 Awd. Pharma Gmbh & Co. Kg Farmaceutické přípravky
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US20030017208A1 (en) * 2002-07-19 2003-01-23 Francis Ignatious Electrospun pharmaceutical compositions

Also Published As

Publication number Publication date
IL174009A (en) 2010-02-17
US7666860B2 (en) 2010-02-23
ES2284049T3 (es) 2007-11-01
CN100548276C (zh) 2009-10-14
DE502004003170D1 (de) 2007-04-19
WO2005023216A2 (de) 2005-03-17
DE10341264A1 (de) 2005-03-24
US20060147524A1 (en) 2006-07-06
WO2005023216A3 (de) 2005-07-28
EP1663160B1 (de) 2007-03-07
ATE355830T1 (de) 2007-03-15
SI1663160T1 (sl) 2007-08-31
PL1663160T3 (pl) 2007-07-31
EP1663160A2 (de) 2006-06-07
IL174009A0 (en) 2006-08-01
MXPA06002530A (es) 2006-06-20
CN1874760A (zh) 2006-12-06
HK1092715A1 (en) 2007-02-16
PE20051041A1 (es) 2006-02-09
PT1663160E (pt) 2007-06-18

Similar Documents

Publication Publication Date Title
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
AR108594A2 (es) Formulaciones farmacéuticas que conservan el sabor con características farmacéuticas mejoradas
AR046773A1 (es) Formulaciones farmaceuticas de bisfosfonatos
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
CY1118179T1 (el) Φαρμακευτικη συνθεση
AR062760A1 (es) Administracion de inhibidores de dipeptidilpetidasa
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
AR048431A1 (es) Formulaciones galenicas de compuestos organicos
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
UY29377A1 (es) Nuevas formilaciones líquidas de rotavirus, su preparación y sus usos.
ECSP066826A (es) Inhibidores de integrasa de vih
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
AR065731A1 (es) Composiciones farmaceuticas que contienen 2-[6-(3-amino-pipenidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-primidin-1-il metil]-4-fluoro-benzonitrilo. uso. metodo de tratamiento, administracion semanal de inhibidores de la dipeptidilpeptidasa.
NO20065078L (no) Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister.
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
AR045564A1 (es) Forma de dosificacion en forma de multiples particulas, formulada mediante fusion . preparado de combinacion farmaceutica
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide
JP2008088189A5 (es)
PE20030830A1 (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea
WO2001074396A8 (en) Composition and method for promoting oral health

Legal Events

Date Code Title Description
FB Suspension of granting procedure